Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance

BACKGROUND: Sacituzumab govitecan is an antibody–drug conjugate that delivers SN-38, an active metabolite of irinotecan, to the target molecule, trophoblast cell-surface antigen 2 (Trop-2). It is a promising drug for triple-negative breast cancer and is anticipated to be effective for luminal breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jing, Wu, Wenwen, Togashi, Yukiko, Taira Nihira, Naoe, Johmura, Yoshikazu, Zhu, Dajiang, Nakanishi, Makoto, Miyoshi, Yasuo, Ohta, Tomohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587948/
https://www.ncbi.nlm.nih.gov/pubmed/35882754
http://dx.doi.org/10.1007/s12282-022-01389-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587948/
https://www.ncbi.nlm.nih.gov/pubmed/35882754
http://dx.doi.org/10.1007/s12282-022-01389-3

Ejemplares similares